Improving circulation aggravates the orthostatic hypotension in a patient with Parkinson's disease: A case report

doi:10.3969/j.issn.1004-583X.2022.10.010

Abstract

Abstract:

Objective To highlight non-motor symptoms in patients with Parkinson's disease (PD). Methods We reported therapeutic outcomes of a PD case with hypertension, who had been treated with anti-PD drugs, antihypertensive therapy and circulation-improving. Results The patient developed severe postural hypotension and syncope during the treatment. Conclusion Non-motor symptoms like orthostatic hypotension in PD patients should be highlighted by clinicians during the treatment.

Key words: Parkinson's disease, orthostatic hypotension, circulation-improving

CLC Number:

R742.5

Li Wenjun, Zhang Ce, Liu Junyan. Improving circulation aggravates the orthostatic hypotension in a patient with Parkinson's disease: A case report[J]. Clinical Focus, 2022, 37(10): 934-937.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2022.10.010

https://huicui.hebmu.edu.cn/EN/Y2022/V37/I10/934

References 24

[1]	Merola A, Romagnolo A, Rosso M, et al. Autonomic dysfunction in Parkinson’s disease: A prospective cohort study[J]. Mov Disord, 2018, 33(3):391-397. doi: 10.1002/mds.27268 URL
[2]	刘军. 中国帕金森病的诊断标准(2016版)[J]. 中华神经科杂志, 2016, 49(4): 268-271.
[3]	张洪英, 吴晶涛, 叶靖, 等. 动脉自旋标记灌注成像观察帕金森病患者皮质下脑区血流代谢[J]. 中华神经科杂志, 2019, 52(9):739-744.
[4]	Melzer TR, Watts R, MacAskill MR, et al. Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson's disease[J]. Brain, 2011, 134 (Pt 3): 845-855 doi: 10.1093/brain/awq377 pmid: 21310726
[5]	Jeong HS, Oh E, Park JS, et al. Longitudinal cerebral perfusion changes in Parkinson’s disease with subjective cognitive impairment[J]. Dement NeurocognDisord, 2016, 15(4):147-152.
[6]	Barzgari A, Sojkova J, Maritza Dowling N, et al. Arterial spin labeling reveals relationships between resting cerebral perfusion and motor learning in Parkinson's disease[J]. Brain Imaging Behav, 2019, 13(3): 577-587. doi: 10.1007/s11682-018-9877-1 pmid: 29744796
[7]	Song IU, Chung YA, Huh R. Brain perfusion SPECTcan differentiate clinical subtypes of Parkinson’s diseases[J]. Int J Imaging Syst Technol, 2013, 23(3): 222-226. doi: 10.1002/ima.22055 URL
[8]	Madhyastha TM, Askren MK, Boord P, et al. Cerebral perfusion and cortical thickness indicate cortical involvement in mild Parkinson’s disease[J]. Mov Disord, 2015, 30(14): 1893-1900. doi: 10.1002/mds.26128 URL
[9]	Le Heron CJ, Wright SL, Melzer TR, et al. Comparing cerebral perfusion in Alzheimer's disease and Parkinson's disease dementia: An ASL-MRI study[J]. J Cereb Blood Flow Metab, 2014, 34(6): 964-970. doi: 10.1038/jcbfm.2014.40 URL
[10]	Taguchi S, Tanabe N, Niwa JI, et al. Motor improvement-related regional cerebral blood flow changes in Parkinson's disease in response to antiparkinsonian drugs[J]. Parkinsons Dis, 2019:7503230.
[11]	Biju KC, Shen Q, Hernandez ET, et al. Reduced cerebral blood flow in an α-synuclein transgenic mouse model of Parkinson's disease[J]. J Cereb Blood Flow Metab, 2020, 40(12):2441-2453. doi: 10.1177/0271678X19895432 URL
[12]	Peng S, Eidelberg D, Ma Y. Brain network markers of abnormal cerebral glucose metabolism and blood flow in Parkinson's disease[J]. Neurosci Bull, 2014, 30(5): 823-837. doi: 10.1007/s12264-014-1472-x pmid: 25260798
[13]	汤旭红, 刘建红. 桂哌齐特的临床应用进展[J]. 中国现代药物应用, 2010, 4(9):223-225.
[14]	Nthenge-Ngumbau DN, Mohanakumar KP. Can cyclic nucleotide phosphodiesterase inhibitors be drugs for Parkinson's disease?[J]. Mol Neurobiol, 2018, 55(1): 822-834. doi: 10.1007/s12035-016-0355-8 pmid: 28062949
[15]	柳丽, 郑静, 黄险峰, 等. 磷酸二酯酶及其抑制剂在神经退行性疾病中的研究进展[J]. 中国药理学与毒理学杂志, 2018, 32(12):953-958.
[16]	蓝兰, 王红梅, 于洋, 等. 马来酸桂哌齐特不良反应文献概述[J]. 中国药物滥用防治杂志, 2017, 23(3):178-179.
[17]	胡鹏洲, 马亮, 郭代红, 等. 541例马来酸桂哌齐特药品不良反应报告及风险因素分析[J]. 中国药物应用与监测, 2016, 13(3):167-170.
[18]	杜艳圣, 张媛, 周庆博. 帕金森病血压调节障碍的研究进展[J]. 中华神经科杂志, 2019, 52(10):847-851.
[19]	周沛萱, 李双庆. 帕金森病患者直立性低血压的研究进展[J]. 中华全科医学, 2018, 16(1):113-117.
[20]	陆杰, 吴亮, 蒋腾, 等. 帕金森病的血压特点与管理[J]. 中华内科杂志, 2016, 55(1):54-56.
[21]	Pilotto A, Romagnolo A, Tuazon JA, et al. Orthostatic hypotension and REM sleep behaviour disorder: Impact on clinical outcomes in α-synucleinopathies[J]. J Neurol Neurosurg Psychiatry, 2019, 90(11):1257-1263. doi: 10.1136/jnnp-2019-320846 pmid: 31142660
[22]	Robinson L, Kimpinski K. Neurogenic orthostatic hypotension impairs information processing speed and attention[J]. Physiol Behav, 2019, 211:112682. doi: 10.1016/j.physbeh.2019.112682 URL
[23]	Hyam JA, Roy HA, Huang Y, et al. Cardiovascular autonomic responses in patients with Parkinson disease to pedunculopontine deep brain stimulation[J]. Clin Auton Res, 2019, 29(6):615-624. doi: 10.1007/s10286-019-00634-8 pmid: 31493114
[24]	Hiorth YH, Pedersen KF, Dalen I, et al. Orthostatic hypotension in Parkinson disease: A 7-year prospective population-based study[J]. Neurology, 2019, 93(6):e1526-e1534. doi: 10.1212/WNL.0000000000008314 URL